Evidence map›Paper›PMID 40064593›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Antifibrotic effects of specific targeting of the 5-hydroxytryptamine 2B receptor (5-HT

Thuong Trinh-Minh, Cuong Tran-Manh, Andrea-Hermina Györfi, Nicholas Dickel, Christoph Liebel, Xiang Zhou, Jiucun Wang, Meik Kunz, Helena Arozenius, Lars Pettersson and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thuong Trinh-MinhDepartment of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Cuong Tran-ManhDepartment of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Andrea-Hermina GyörfiDepartment of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0002-4960-3369
Nicholas DickelChair of Medical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Christoph LiebelDepartment of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Xiang ZhouDepartment of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Jiucun WangState Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0003-2765-0620
Meik KunzChair of Medical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Helena ArozeniusAnaMar AB, Stockholm, Sweden.
Lars PetterssonAnaMar AB, Stockholm, Sweden.
Sam LindgrenAnaMar AB, Stockholm, Sweden.
Christina WenglénAnaMar AB, Stockholm, Sweden.
Jörg H W DistlerDepartment of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0001-7408-9333

Funding

AnaMarCareer Support Award of Medicine of the Ernst Jung Foundation and an unrestricted research grant from the Hiller-Foundation.Deutsche Forschungsgemeinschaft DI 1537/14-1Deutsche Forschungsgemeinschaft DI 1537/17-1Deutsche Forschungsgemeinschaft DI 1537/20-1Deutsche Forschungsgemeinschaft DI 1537/22-1Deutsche Forschungsgemeinschaft DI 1537/23-1Deutsche Forschungsgemeinschaft DI1537/27-1Deutsche Forschungsgemeinschaft DI1537/28-1Deutsche Forschungsgemeinschaft GRK2740(B02)Deutsche Forschungsgemeinschaft SFBCRC1181(projectC01)Deutsche Forschungsgemeinschaft SFBTR221/324392634(B04)Deutsche Forschungsgemeinschaft SFBTR221/324392634(INF)ELAN-Foundation Erlangen 21-07-23-1Else Kröner-Fresenius-Stiftung 2014_A184Else Kröner-Fresenius-Stiftung 2014_A47German Federal Ministry of Education and Research (BMBF) CompLS program grant 031L0262CGerman Federal Ministry of Education and Research (BMBF) MASCARA program, TP 2 (01EC1903A)Medical Faculty of Heinrich-Heine University Düsseldorf (FoKo) ID 2022-18Medical Faculty of Heinrich-Heine University Düsseldorf (FoKo) ID 2023-31Medical Faculty of Heinrich-Heine University Düsseldorf (FoKo) ID 2023-33National Science Foundation of China 82030003Wilhelm Sander-Stiftung 2013.056.1
6 · The paper itself

Abstract

objectiveSystemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case-specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options. Here, we evaluated the therapeutic effects of the highly selective 5-hydroxytryptamine 2B receptor (5-HT

methodsThe antifibrotic effects of AM1476 were evaluated in the mouse models of bleomycin-induced pulmonary fibrosis in Tsk-1 mice and in mice with sclerodermatous chronic graft-versus-host disease. For further validation, the antifibrotic effects of AM1476 were analyzed in precision cut skin (PCS) slices from patients with SSc.

resultsAM1476 demonstrated high selectivity for 5-HT

conclusionWe describe AM1476 as a highly selective inhibitor of 5-HT

Indexed as

Pulmonary FibrosisReceptor, Serotonin, 5-HT2BScleroderma, SystemicSerotonin 5-HT2 Receptor AntagonistsSkinAnimalsBleomycinDisease Models, AnimalFemaleFibrosisGraft vs Host DiseaseHumansMiceBleomycinReceptor, Serotonin, 5-HT2BSerotonin 5-HT2 Receptor Antagonists

Identifiers

PMID40064593
PMCPMC12311259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.